Display Settings:

Format

Send to:

Choose Destination
    Neurology. 2004 Aug 24;63(4):718-20.

    Randomized pilot trial of high-dose betaINF-1a in patients with inclusion body myositis.

    Source

    Neuromuscular Disease Center, 601 Elmwood Avenue, Box 673, Rochester, NY 14642-8673. Rabi_Tawil@URMC.Rochester.edu

    Abstract

    Beta-interferon-1a (betaINF-1a) is well tolerated at low dose (30 microg IM/week) in inclusion body myositis (IBM). The authors investigated the safety and tolerability of high-dose (60 microg IM/week) betaINF-1a in a randomized, placebo-controlled trial in IBM. Twenty-seven of the 30 subjects enrolled completed the study. The adverse event profile was similar for the placebo and betaINF-1a groups. betaINF-1a, at a dose of 60 microg IM/week, is well tolerated in IBM, but no differences in muscle strength or mass were observed between the placebo and betaINF-1a groups at 6 months in this pilot study.

    PMID:
    15326251
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for HighWire Press

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk